Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794496

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794496

Mpox Therapeutics

PUBLISHED:
PAGES: 282 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Mpox Therapeutics Market to Reach US$132.7 Million by 2030

The global market for Mpox Therapeutics estimated at US$90.0 Million in the year 2024, is expected to reach US$132.7 Million by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Smallpox Vaccine, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$75.5 Million by the end of the analysis period. Growth in the Antivirals segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.5 Million While China is Forecast to Grow at 10.3% CAGR

The Mpox Therapeutics market in the U.S. is estimated at US$24.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.2 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Mpox Therapeutics Market - Key Trends & Drivers Summarized

Why Are Antiviral Treatments Central in Mpox Care?

Antiviral treatments are crucial in managing severe mpox cases and limiting complications. These treatments help reduce viral replication once infection is confirmed. Currently available options include antiviral drugs originally developed for related viruses. Access to effective therapeutics enables clinicians to treat high-risk patients, such as immunocompromised individuals, pregnant persons, and children. Early intervention with antiviral therapy improves patient outcomes and reduces the risk of severe disease progression.

Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.

What New Treatments Are Emerging or Under Study?

Research into novel therapies has intensified due to rising mpox incidence and growing public health interest. Experimental drugs targeting viral replication mechanisms are in various stages of clinical development. Some candidates offer broader antiviral activity. Others are designed specifically for mpox. Research efforts also include evaluating monoclonal antibodies aimed at neutralizing the virus. These treatments may offer passive immunity and support for severe or refractory cases.

Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.

How Are Access and Distribution Evolving?

Mpox therapeutics are being distributed through public health channels, emergency stockpiles, and international aid programs. Partnerships between government agencies, non-governmental organizations, and manufacturers facilitate medicine allocation in low-resource regions. Programs often include training for clinicians to identify eligible patients, manage treatment regimens, and monitor for adverse events. This coordinated approach helps ensure equitable treatment access in outbreak zones.

Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.

Growth in the Mpox Therapeutics Market Is Driven by Several Factors…

Growth in the mpox therapeutics market is driven by several factors. Rising global mpox cases have increased demand for effective treatments. Emergency authorizations and approvals of new antiviral agents support market expansion. Investment in clinical trials targeting safety and efficacy in vulnerable populations advances therapeutic options. Scale-up of manufacturing capacity and flexible supply chains improves access in diverse settings. Expansion of international aid programs enables distribution in low-resource regions. Growing focus on combination therapies and monoclonal antibodies broadens treatment portfolios and supports future innovation.

SCOPE OF STUDY:

The report analyzes the Mpox Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aegis Sciences Corporation
  • Bavarian Nordic A/S
  • Baxter International Inc.
  • BioNTech SE
  • Chimerix Inc.
  • CIDIC Company Limited
  • Emergent BioSolutions Inc.
  • Emcure Pharmaceuticals Ltd.
  • Gilead Sciences Inc.
  • Hetero Drugs Limited
  • Mylan N.V. (Viatris)
  • Moderna Inc.
  • Olon S.p.A.
  • Piramal Enterprises Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • SIGA Technologies Inc.
  • SymBio Pharmaceuticals Ltd.
  • Teva Pharmaceutical Ltd.
  • Tonix Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37449

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mpox Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Case Burden in Urban and Non-Endemic Regions Drives Demand for Targeted Mpox Treatments
    • Emergency Use Authorization Pathways Spur Accelerated Development of Antiviral Therapies
    • Expansion of Zoonotic Virus Research Throws Spotlight on Broader-Spectrum Antiviral Agents
    • Government Funding and Global Health Partnerships Propel Clinical Trials for Investigational Drugs
    • Increased Use of Tecovirimat and Cidofovir Strengthens Short-Term Market for Repurposed Therapies
    • Vaccine-Linked Immunotherapies Generate Adjacent Market Demand for Prophylactic-Therapeutic Combos
    • Outbreak Management Strategies Support Parallel Growth in Therapeutics Alongside Diagnostics
    • Cross-Application of Smallpox Therapeutics in Mpox Management Sustains Off-Label Prescriptions
    • Focus on Reducing Hospitalization and Complication Rates Enhances Demand for Fast-Acting Treatments
    • Public Health Policies Supporting Post-Exposure Treatment Create Stable Demand for Rapid-Response Drugs
    • Expansion of National Stockpiles and Strategic Reserves Drives Procurement of Antiviral Therapeutics
    • Rising Demand for Oral and Injectable Formulations Supports Diverse Product Delivery Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mpox Therapeutics Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mpox Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Smallpox Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Smallpox Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Smallpox Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccinia Immune Globulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccinia Immune Globulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccinia Immune Globulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Mpox Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Mpox Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Mpox Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Mpox Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!